β-内酰胺酶抑制剂增强β-内酰胺类抗生素与达托霉素对耐甲氧西林金黄色葡萄球菌的协同作用。
β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.
作者信息
Henson Karl Evans R, Yim Juwon, Smith Jordan R, Sakoulas George, Rybak Michael J
机构信息
Division of Infectious Diseases, Wayne State University and Detroit Medical Center, Detroit, Michigan, USA.
Anti-infective Research Laboratory, Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, Michigan, USA.
出版信息
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01564-16. Print 2017 Jan.
Abstract
The evidence for using combination therapy for the treatment of serious methicillin-resistant Staphylococcus aureus (MRSA) infections is growing. In this study, we investigated the synergistic effect of daptomycin (DAP) combined with piperacillin-tazobactam and ampicillin-sulbactam against MRSA in time-kill experiments. Six of eight strains demonstrated synergy between DAP and the β-lactam-β-lactamase inhibitor (BLI) combination. In 5/8 strains, the synergy occurred only in the presence of the BLI, highlighting a role for BLIs in peptide-β-lactam synergy.
摘要
使用联合疗法治疗严重耐甲氧西林金黄色葡萄球菌（MRSA）感染的证据越来越多。在本研究中，我们在时间杀菌实验中研究了达托霉素（DAP）与哌拉西林 - 他唑巴坦以及氨苄西林 - 舒巴坦联合对MRSA的协同作用。8株菌株中有6株显示DAP与β-内酰胺 - β-内酰胺酶抑制剂（BLI）组合之间存在协同作用。在8株菌株中的5株中，协同作用仅在BLI存在时发生，突出了BLI在肽 - β-内酰胺协同作用中的作用。
相似文献
1
β-Lactamase Inhibitors Enhance the Synergy between β-Lactam Antibiotics and Daptomycin against Methicillin-Resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2016 Dec 27;61(1). doi: 10.1128/AAC.01564-16. Print 2017 Jan.
2
Classical β-Lactamase Inhibitors Potentiate the Activity of Daptomycin against Methicillin-Resistant Staphylococcus aureus and Colistin against Acinetobacter baumannii.
Antimicrob Agents Chemother. 2017 Jan 24;61(2). doi: 10.1128/AAC.01745-16. Print 2017 Feb.
3
Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
Antimicrob Agents Chemother. 2016 Jun 20;60(7):3970-5. doi: 10.1128/AAC.01666-15. Print 2016 Jul.
4
Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2004 Aug;48(8):2871-5. doi: 10.1128/AAC.48.8.2871-2875.2004.
5
6
In vitro synergistic activity of colistin with tigecycline or β-lactam antibiotic/β-lactamase inhibitor combinations against carbapenem-resistant Acinetobacter baumannii.
J Int Med Res. 2013 Dec;41(6):1830-7. doi: 10.1177/0300060513496172.
7
Vancomycin and piperacillin-tazobactam against methicillin-resistant Staphylococcus aureus and vancomycin-intermediate Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model.
Clin Ther. 2014 Oct 1;36(10):1334-44. doi: 10.1016/j.clinthera.2014.06.027. Epub 2014 Jul 25.
8
β-Lactams increase the antibacterial activity of daptomycin against clinical methicillin-resistant Staphylococcus aureus strains and prevent selection of daptomycin-resistant derivatives.
Antimicrob Agents Chemother. 2012 Dec;56(12):6192-200. doi: 10.1128/AAC.01525-12. Epub 2012 Sep 17.
9
Analysis of synergy between beta-lactams and anti-methicillin-resistant Staphylococcus aureus agents from the standpoint of strain characteristics and binding action.
J Infect Chemother. 2019 Apr;25(4):273-280. doi: 10.1016/j.jiac.2018.12.007. Epub 2019 Jan 31.
10
Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.
Nat Chem Biol. 2015 Nov;11(11):855-61. doi: 10.1038/nchembio.1911. Epub 2015 Sep 14.
引用本文的文献
1
A new approach to overcoming antibiotic-resistant bacteria: Traditional Chinese medicine therapy based on the gut microbiota.
Front Cell Infect Microbiol. 2023 Apr 6;13:1119037. doi: 10.3389/fcimb.2023.1119037. eCollection 2023.
2
Targeting the Holy Triangle of Quorum Sensing, Biofilm Formation, and Antibiotic Resistance in Pathogenic Bacteria.
Microorganisms. 2022 Jun 16;10(6):1239. doi: 10.3390/microorganisms10061239.
3
Select controversies in the management of methicillin-resistant bacteremia: answers and remaining questions from recent evidence.
Fac Rev. 2021 Aug 31;10:66. doi: 10.12703/r/10-66. eCollection 2021.
4
Synergistic Anti-MRSA Activity of Cationic Nanostructured Lipid Carriers in Combination With Oxacillin for Cutaneous Application.
Front Microbiol. 2018 Jul 4;9:1493. doi: 10.3389/fmicb.2018.01493. eCollection 2018.
5
Combination of Tedizolid and Daptomycin against Methicillin-Resistant Staphylococcus aureus in an Model of Simulated Endocardial Vegetations.
Antimicrob Agents Chemother. 2018 Apr 26;62(5). doi: 10.1128/AAC.00101-18. Print 2018 May.
本文引用的文献
1
Daptomycin in Combination with Ceftolozane-Tazobactam or Cefazolin against Daptomycin-Susceptible and -Nonsusceptible Staphylococcus aureus in an In Vitro, Hollow-Fiber Model.
Antimicrob Agents Chemother. 2016 Jun 20;60(7):3970-5. doi: 10.1128/AAC.01666-15. Print 2016 Jul.
2
Penicillin Binding Protein 1 Is Important in the Compensatory Response of Staphylococcus aureus to Daptomycin-Induced Membrane Damage and Is a Potential Target for β-Lactam-Daptomycin Synergy.
Antimicrob Agents Chemother. 2015 Nov 2;60(1):451-8. doi: 10.1128/AAC.02071-15. Print 2016 Jan.
3
Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA.
Nat Chem Biol. 2015 Nov;11(11):855-61. doi: 10.1038/nchembio.1911. Epub 2015 Sep 14.
4
The combination of ceftaroline plus daptomycin allows for therapeutic de-escalation and daptomycin sparing against MRSA.
J Antimicrob Chemother. 2015 Feb;70(2):505-9. doi: 10.1093/jac/dku378. Epub 2014 Sep 22.
5
Antimicrobial salvage therapy for persistent staphylococcal bacteremia using daptomycin plus ceftaroline.
Clin Ther. 2014 Oct 1;36(10):1317-33. doi: 10.1016/j.clinthera.2014.05.061. Epub 2014 Jul 10.
6
Evaluation of ceftaroline, vancomycin, daptomycin, or ceftaroline plus daptomycin against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro pharmacokinetic/pharmacodynamic model of simulated endocardial vegetations.
Antimicrob Agents Chemother. 2014 Jun;58(6):3177-81. doi: 10.1128/AAC.00088-14. Epub 2014 Mar 24.
7
β-Lactam antibiotics targeting PBP1 selectively enhance daptomycin activity against methicillin-resistant Staphylococcus aureus.
Antimicrob Agents Chemother. 2013 Oct;57(10):5005-12. doi: 10.1128/AAC.00594-13. Epub 2013 Jul 29.
8
Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamic model.
Antimicrob Agents Chemother. 2013 Jan;57(1):66-73. doi: 10.1128/AAC.01586-12. Epub 2012 Oct 15.
9
Addition of ceftaroline to daptomycin after emergence of daptomycin-nonsusceptible Staphylococcus aureus during therapy improves antibacterial activity.
Antimicrob Agents Chemother. 2012 Oct;56(10):5296-302. doi: 10.1128/AAC.00797-12. Epub 2012 Aug 6.
10
Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
Antimicrob Agents Chemother. 2010 Dec;54(12):5187-92. doi: 10.1128/AAC.00536-10. Epub 2010 Oct 4.
Zotero 插件